Cirrhosis laboratory findings: Difference between revisions

Jump to navigation Jump to search
Line 28: Line 28:
**[[Hemolysis]]
**[[Hemolysis]]
* '''[[Coagulation defects]]''' - the [[liver]] produces most of the coagulation factors and thus coagulopathy correlates with worsening liver disease.
* '''[[Coagulation defects]]''' - the [[liver]] produces most of the coagulation factors and thus coagulopathy correlates with worsening liver disease.
* '''[[Ascitic fluid analysis]]''' - Most experts recommend a diagnostic [[paracentesis]] be performed if the ascites is new or if the patient with ascites is being admitted to the hospital. The fluid is then reviewed for its gross appearance, protein level, [[serum albumin|albumin]], and cell counts (red and white). Additional tests will be performed if indicated such as [[Gram stain]] and [[cytology]].<ref name=OTM>Warrell DA, Cox TN, Firth JD, Benz ED. ''Oxford textbook of medicine''. Oxford: Oxford University Press, 2003. ISBN 0-19-262922-0.</ref>
** The '''[[Serum-ascites albumin gradient]]''' (SAAG) is probably a better discriminant than older measures (transudate versus exudate) for the causes of ascites.<ref>Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. ''Ann Intern Med'' 1992;117:215-20. PMID 1616215.</ref> A high gradient (> 1.1 g/dL) indicates the ascites is due to portal hypertension. A low gradient (< 1.1 g/dL) indicates ascites of non-portal hypertensive etiology. Ascites is broadly classified as two types based on the [[Serum-ascites albumin gradient]] (SAAG):
*** Transudate - SAAG > 1.1 g/dL (indicates the ascites is due to [[portal hypertension]]).
*** Exudate - SAAG < 1.1 g/dL (indicates the ascites is due to non-portal hypertension etiology).


There is now a validated and patented combination of 6 of these markers as non-invasive biomarkers of fibrosis (and so of cirrhosis) : [[FibroTest]].<ref name="pmid18973844">{{cite journal |author= Halfon P, Munteanu M, Poynard T|title= FibroTest-ActiTest as a non-invasive marker of liver fibrosis  |journal= Gastroenterol Clin Biol |volume=32|issue=6 |pages=22–39 |year=2008 |pmid= 18973844 |doi=10.1016/S0399-8320(08)73991-5}}</ref>
There is now a validated and patented combination of 6 of these markers as non-invasive biomarkers of fibrosis (and so of cirrhosis) : [[FibroTest]].<ref name="pmid18973844">{{cite journal |author= Halfon P, Munteanu M, Poynard T|title= FibroTest-ActiTest as a non-invasive marker of liver fibrosis  |journal= Gastroenterol Clin Biol |volume=32|issue=6 |pages=22–39 |year=2008 |pmid= 18973844 |doi=10.1016/S0399-8320(08)73991-5}}</ref>

Revision as of 14:27, 7 September 2012

Cirrhosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Cirrhosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case studies

Case #1

Cirrhosis laboratory findings On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cirrhosis laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cirrhosis laboratory findings

CDC on Cirrhosis laboratory findings

Cirrhosis laboratory findings in the news

Blogs on Cirrhosis laboratory findings

Directions to Hospitals Treating Cirrhosis

Risk calculators and risk factors for Cirrhosis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

A range of laboratory values need to be obtained in the evaluation of cirrhosis, both to determine the severity of the disease, and to determine the causative factor. Liver function tests, complete blood count, basic metabolic panel and coagulation factors are standard in the evaluation of cirrhosis. More specific testing for markers and serum enzymes can be done when certain genetic causes and etiologies are suspected.

Laboratory Findings

The following findings are typical in cirrhosis:

There is now a validated and patented combination of 6 of these markers as non-invasive biomarkers of fibrosis (and so of cirrhosis) : FibroTest.[3]

Other laboratory studies performed in newly diagnosed cirrhosis may include:

References

  1. Warrell DA, Cox TN, Firth JD, Benz ED. Oxford textbook of medicine. Oxford: Oxford University Press, 2003. ISBN 0-19-262922-0.
  2. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchison JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215-20. PMID 1616215.
  3. Halfon P, Munteanu M, Poynard T (2008). "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". Gastroenterol Clin Biol. 32 (6): 22–39. doi:10.1016/S0399-8320(08)73991-5. PMID 18973844.

Template:WH

Template:WS